Abstracts tagged "autoimmune diseases"

Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 1483 • ACR Convergence 2025
Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
Fernanda M. Garcia-Garcia¹, Oscar Azael Garza-Flores², Esteban C. Garza-Gonzalez³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú¹, Dionicio A. Galarza-Delgado¹, Iris J. Colunga-Pedraza¹, Jesus Alberto Cardenas-de la Garza⁵, Jose R Azpiri-Lopez⁶ and Victor M Fraga-Enriquez⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and accelerated atherosclerosis, leading to increased cardiovascular (CV) risk. While CV…
Abstract Number: 1303 • ACR Convergence 2025
Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Xuemei Tang, Yuting Zhou, Yuxiao Chen, Xinglin Wu and Qiang Luo, Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic)
Background/Purpose: A balanced diet can prevent diseases and promote physical and mental health. Accumulating evidence shows that fruits and vegetables (F&Vs) intake is associated with…
Abstract Number: 1157 • ACR Convergence 2025
Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Ella Steiner¹, Ioana Andreica², Stefanie Reale³, Gianna Chierego⁴, Philipp Köhler⁵, Sonja Zapke⁴, Benjamin Wilde⁶, David Kiefer⁷, Philipp Sewerin², Hilal Kavruk⁵, Dimitra Karagkiozidou⁵, Panagiotis Ermeidis⁵, Barbara Guminski⁵, Andreas Kribben⁶, Jürgen Braun⁸, Xenofon Baraliakos⁹ and Uta Kiltz⁹, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Nordrhein-Westfalen, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶University Hospital, Nephrology, Essen, Essen, Germany, ⁷Private practice of rheumatology, Hattingen, Germany, ⁸Ruhr-University, Bochum, Germany; and Rheumatologische Versorgungszentrum (RVZ) Steglitz, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common among older adults, with a lifetime risk of 25%. The risk is particularly increased in individuals with immunosuppression such…
Abstract Number: 1006 • ACR Convergence 2025
AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody
Yun Zhang, Hao Ran, Tianhong Li, Liguo Dong, Chenpeng Su, Chuan Chen, Lisha Dong, Dandan Liu, Yi Pan, Xiaoou Xu, Xiaoqian Chen, Liang Tian, Jian Peng and Zhenping Zhu, Helixon Therapeutics, New York
Background/Purpose: The itch-scratch cycle in atopic dermatitis (AD) is closely linked to skin inflammation exacerbation, which not only accelerates disease progression but also significantly impacts…
Abstract Number: 0946 • ACR Convergence 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Juan Liang¹ and Ting Wang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…
Abstract Number: 0902 • ACR Convergence 2025
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
Deisy Muriel Velez arteaga¹, Yemil Atisha Fregoso², Hasret Gunduz³ and Betty Diamond⁴, ¹The Elmezzi School of Molecular Medicine, New Rochelle, NY, ²The Feinstein Institute, Long Island, NY, ³The Feinstein Institute, Long Island, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Studying antinuclear antibody (ANA) producing B cells at the single-cell level offers critical insights into their fine specificity and functional characteristics. However, conventional techniques…
Abstract Number: 0558 • ACR Convergence 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana¹, Marta Polak¹, Sharan Nischal¹, Elizabeth Chen¹, Deepika Balakrishna², Ching-Heng Chou¹, Christopher Sisk³, Lynn Tomsho¹, Arun Kannan¹, Cynthia DeKlotz¹, Megan Miller⁴, Joseph Cafone³, Paul Newbold¹, Ya-Wen Yang¹, Monica Leung¹, Dawn Waterworth¹, Nina Sabins¹, Anna Perillo⁵, Andreas Pinter⁶ and Robert Bissonnette⁷, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ²Johnson & Johnson, San Diego, CA, USA, San Diego, USA, ³Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ⁵The Rockefeller University, New York, NY, USA, New York, NY, ⁶Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany, ⁷Innovaderm Research, Montreal, QC, Canada, Montreal, QC
Background/Purpose: Icotrokinra (ICO), a first-in-class targeted oral peptide that blocks the interleukin (IL)-23R and inhibits IL-23 pathway signaling, is being evaluated in the phase 3…
Abstract Number: 0510 • ACR Convergence 2025
A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease
Anna-Maria Hoffmann-Vold¹, Kastriot Kastrati², Marco Sprecher³, Emily Violette Langballe¹, Phuong Diep¹, Havard Fretheim¹, Helena Andersson¹, Paul Studenic⁴, Bojana Müller-Durovic³, Cathrine Brunborg¹, Cosimo Bruni⁵, Christian Clarenbach³, Thomas Frauenfelder⁶, Trond Mogens Aaløkken¹, Natasha Moe¹, Helmut Prosch⁴, Helga Radner², Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Univeristy Hospital Zurich, Zurich, Switzerland, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁷Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of Sjögren disease (SjD) patients, leading to increased morbidity and reduced survival. The true prevalence may be higher…
Abstract Number: 0300 • ACR Convergence 2025
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Reena Yaman¹, Archit Srivastava², Alejandro Arango Martinez³, Caroyln Harvey⁴, Ronald Butendieck⁵, Vikas Majithia⁶ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Universidad Pontificia Bolivariana, Medellín, Colombia, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic Florida, Jacksonville, ⁶Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
Abstract Number: 0256 • ACR Convergence 2025
The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Kari Falaas¹, Lyubov Tiegs² and Elie Gertner³, ¹University of Minnesota, Minneapolis, ²University of Minnesota, Mineapolis, ³Regions Hospital, St. Paul, MN
Background/Purpose: Rheumatologists are increasingly involved in the management of patients with severe manifestations of rheumatologic disease treated with Extracorporeal Membrane Oxygenation (ECMO). A 2020 systematic…
Abstract Number: 0161 • ACR Convergence 2025
Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Madiha Naqsh Siddiqui¹, Yen Chen¹, Rosemary Gedert², Suiyuan Huang², Dinesh Khanna² and John Varga², ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Malignancies are one of the leading causes of non-systemic sclerosis-related mortality in patients with systemic sclerosis (SSc)1, with lung cancer being the most common…
Abstract Number: 0044 • ACR Convergence 2025
DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Rufei Lu¹, Tayte Stephens², Carla Guthridge¹, Miles Smith¹, Joseph Kheir¹, Cristina Arriens¹, Joan Merrill³, Marci Beel⁴, Susan Macwana¹, Wade DeJager⁵, Nicholas Domingez¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Science Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁴Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with distinct clinical and immunopathological features. Epigenetic modifications, particularly DNA methylation, contribute to…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].